These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1872309)

  • 41. Clinical pharmacology of sulfonylureas.
    Melander A
    Metabolism; 1987 Feb; 36(2 Suppl 1):12-6. PubMed ID: 3543616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination insulin-sulfonylurea therapy in type II diabetes mellitus.
    Allen BT; Feinglos MN
    South Med J; 1987 Oct; 80(10):1285-9. PubMed ID: 3310252
    [No Abstract]   [Full Text] [Related]  

  • 43. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination use of sulfonylureas and insulin in the treatment of noninsulin-dependent diabetes mellitus.
    Montgomery PA
    Pharmacotherapy; 1992; 12(4):292-9. PubMed ID: 1518728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.
    Halter JB; Ward WK; Porte D; Best JD; Pfeifer MA
    Am J Med; 1985 Aug; 79(2B):6-12. PubMed ID: 2863979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategies for insulin therapy in type 2 diabetes.
    Edelman SV; Morello CM
    South Med J; 2005 Mar; 98(3):363-71. PubMed ID: 15813164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Progress in insulin therapy of NIDDM].
    Kuzuya H
    Nihon Naika Gakkai Zasshi; 1991 Mar; 80(3):354-7. PubMed ID: 1856547
    [No Abstract]   [Full Text] [Related]  

  • 49. Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
    Kanat M
    Med Hypotheses; 2007; 68(6):1228-32. PubMed ID: 17145138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
    Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
    Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.
    Melander A
    Diabetes; 2004 Dec; 53 Suppl 3():S151-5. PubMed ID: 15561903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulfonylureas in the treatment of diabetes mellitus--1985.
    Gerich JE
    Mayo Clin Proc; 1985 Jul; 60(7):439-43. PubMed ID: 3925246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.
    Groop L; Schalin C; Franssila-Kallunki A; Widén E; Ekstrand A; Eriksson J
    Am J Med; 1989 Aug; 87(2):183-90. PubMed ID: 2757059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA; Zinman B; Campos RV; Strack T;
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs.
    Mohan V; Snehalatha C; Ramachandran A; Viswanathan M
    J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Insulin treatment of Type II diabetes].
    Berger W; Waeber C; Tatti V
    Schweiz Rundsch Med Prax; 1990 Oct; 79(41):1233-6. PubMed ID: 2237054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensive insulin therapy in insulin dependent diabetes and combination therapy.
    Spollett GR
    Nurse Pract; 1993 Jul; 18(7):27-8, 33, 36-8. PubMed ID: 8351084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.